From Name:
From Email:
To Name:
To Email:

Optional Message:

FDA approves Gen-Probe's prostate cancer diagnostic test

from Proactive Investors

Gen-Probe said U.S. health regulators approved its diagnostic test Progensa PAC3 which is used to verify the need for repeat biopsies in men at risk of getting prostate cancer. The company makes molecular diagnostic products and services to diagnose diseases and screen donated blood. Gen-Probe acquired worldwide diagnostics rights to the biomarker Prostate Cancer Antigen 3 gene from DiagnoCure in 2003. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063